First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach.
J Immunother Cancer
; 8(1)2020 04.
Article
em En
| MEDLINE
| ID: mdl-32273346
ABSTRACT
BACKGROUND:
First-in-human (FIH) clinical trials require careful selection of a safe yet biologically relevant starting dose. Typically, such starting doses are selected based on toxicity studies in a pharmacologically relevant animal model. However, with the advent of target-specific and highly active immunotherapeutics, both the Food and Drug Administration and the European Medicines Agency have provided guidance that recommend determining a safe starting dose based on a minimum anticipated biological effect level (MABEL) approach.METHODS:
We recently developed a T cell activating bispecific antibody that effectively treats orthotopic patient-derived malignant glioma and syngeneic glioblastoma in mice (hEGFRvIIICD3 bi-scFv). hEGFRvIIICD3 bi-scFv is comprized of two single chain antibody fragments (bi-scFvs) that bind mutant epidermal growth factor receptor variant III (EGFRvIII), a mutation frequently seen in malignant glioma, and human CD3ε on T cells, respectively. In order to establish a FIH dose, we used a MABEL approach to select a safe starting dose for hEGFRvIIICD3 bi-scFv, based on a combination of in vitro data, in vivo animal studies, and theoretical human receptor occupancy modeling.RESULTS:
Using the most conservative approach to the MABEL assessment, a dose of 57.4 ng hEGFRvIIICD3 bi-scFv/kg body weight was selected as a safe starting dose for a FIH clinical study.CONCLUSIONS:
The comparison of our MABEL-based starting dose to our in vivo efficacious dose and the theoretical human receptor occupancy strongly supports that our human starting dose of 57.4 ng hEGFRvIIICD3 bi-scFv/patient kg will be safe.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Complexo CD3
/
Anticorpos Biespecíficos
/
Receptores ErbB
/
Glioma
/
Modelos Teóricos
/
Anticorpos Monoclonais
Tipo de estudo:
Guideline
/
Prognostic_studies
Limite:
Animals
/
Female
/
Humans
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article